Tweet
Haemonetics Co. (NYSE:HAE) has been given an average rating of “Buy” by the six brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $119.00.
HAE has been the subject of several recent research reports. Zacks Investment Research lowered shares of Haemonetics from a “hold” rating to a “sell” rating in a report on Thursday, January 24th. Barrington Research boosted their price target on shares of Haemonetics to $112.00 and gave the company a “positive” rating in a report on Wednesday, February 6th. Finally, ValuEngine lowered shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 5th. Get Haemonetics alerts:
NYSE:HAE opened at $88.13 on Friday. Haemonetics has a one year low of $69.15 and a one year high of $117.56. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.44 and a quick ratio of 1.64. The stock has a market capitalization of $4.57 billion, a PE ratio of 47.13, a price-to-earnings-growth ratio of 2.85 and a beta of 0.89. Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. Haemonetics had a net margin of 4.84% and a return on equity of 17.05%. The business had revenue of $247.36 million during the quarter, compared to analyst estimates of $250.12 million. During the same quarter in the previous year, the business posted $0.62 EPS. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. Research analysts forecast that Haemonetics will post 2.33 earnings per share for the current year.
In related news, VP Dan Goldstein sold 1,693 shares of the business’s stock in a transaction that occurred on Monday, December 10th. The shares were sold at an average price of $102.91, for a total transaction of $174,226.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website . Also, SVP Jacqueline Scanlan sold 1,027 shares of the business’s stock in a transaction that occurred on Wednesday, December 12th. The stock was sold at an average price of $104.22, for a total transaction of $107,033.94. The disclosure for this sale can be found here . In the last quarter, insiders have sold 19,112 shares of company stock valued at $1,833,419. 1.04% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of HAE. Financial Gravity Companies Inc. purchased a new stake in Haemonetics during the 4th quarter worth approximately $41,000. We Are One Seven LLC purchased a new stake in Haemonetics during the 4th quarter worth approximately $51,000. Hanseatic Management Services Inc. grew its position in Haemonetics by 8,500.0% during the 4th quarter. Hanseatic Management Services Inc. now owns 1,462 shares of the medical instruments supplier’s stock worth $146,000 after purchasing an additional 1,445 shares during the last quarter. Ffcm LLC grew its position in Haemonetics by 134.4% during the 4th quarter. Ffcm LLC now owns 1,744 shares of the medical instruments supplier’s stock worth $174,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Advisor Group Inc. grew its position in Haemonetics by 614.5% during the 4th quarter. Advisor Group Inc. now owns 2,022 shares of the medical instruments supplier’s stock worth $203,000 after purchasing an additional 1,739 shares during the last quarter. Hedge funds and other institutional investors own 98.46% of the company’s stock.
About Haemonetics
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. Haemonetics Haemonetics
